Icaritin
- Generic Name
- Icaritin
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20O6
- CAS Number
- 118525-40-9
- Unique Ingredient Identifier
- UFE666UELY
- Background
Icaritin has been used in trials studying the treatment of Solid Tumors, Metastatic Breast Cancer, and Hepatocellular Carcinoma (HCC).
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT01972672
- Locations
- 🇨🇳
Beijing Shenogen Biomedical Co., Ltd, Beijing, Beijing, China
🇨🇳NanJing PLA 81 Hospital, Nanjing, Jiangsu, China
🇨🇳Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01278810
- Locations
- 🇨🇳
Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath